Clinical Data

AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer

BioSpace

Cancer cocktails pairing Moderna's mRNA-4359 with Merck's Keytruda and Marengo's invikafusp alfa with Gilead Sciences' Trodelvy showed promising results, while a complex combination by Agenus and MiNK

Oncology

Read full story

pharminent April 28, 2026 (Last updated: April 28, 2026)

BioSpace

Cancer cocktails pairing Moderna’s mRNA-4359 with Merck’s Keytruda and Marengo’s invikafusp alfa with Gilead Sciences’ Trodelvy showed promising results, while a complex combination by Agenus and MiNK

Oncology

Read full story

Related Stories

Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3

Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Oruka surges as long-acting psoriasis drug shows early promise

You May Have Missed

Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3

AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

GSK eyes October FDA verdict on chronic hep B drug